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BACKGROUND

Oncology and Reproductive Medicine, UT MD Anderson Cancer Center, Houston, TX

 Endometrial
cancer is the most common
.
gynecologic cancer in the United States with
over 66,000 women diagnosed in 2020.

 This multicenter study is a two-stage, randomized phase II trial of the LIUD alone or in
combination with everolimus for the treatment of patients with AH or stage Ia, grade 1
EEC.

 The standard of care for early stage
endometrial cancer is complete surgical
resection.

 In the first stage , patients without prior treatment with have LIUD placed at the time of
confirmatory dilation and curettage.

 The average age for women diagnosed with
endometrial cancer is 60 years, however,
25% of patients are premenopausal and
many are still of childbearing age.
 Surgical resection may not the ideal course
of action for young women who want children
in the future or women who are unable to
have the surgery performed due to medical
co-morbidities.

 Patients will have adequate organ and bone marrow function.
 Well controlled diabetes is permitted on study.

 Biopsy obtained after 3 months of treatment.
 Those patients that have residual disease are deemed progesterone resistant and
proceed to the second stage.
 Patients with LIUD in place for at least 3 months prior to study that have residual disease
are deemed progesterone resistant will progress immediately to second stage.

 In stage 2, if progesterone resistance is identified, patients are randomized to either
the LIUD alone or in combination with everolimus.

STUDY SCHEMA

 The levonorgestrel intrauterine device (LIUD)
releases a consistent dose of progesterone
into the uterine cavity for five years.
 LIUD has been used in lieu of a surgical
resection for atypical hyperplasia (AH) and
grade 1 endometrioid endometrial carcinoma
(EEC) with response rates for 85% and 65%,
respectively, but resistance to progesterone
can be observed.

ENROLLMENT
 Approximately 270 women with AH or grade 1 EEC will participate in the first stage of
the study.
 We will randomize 80 patients in the second stage to achieve adequate power to
detect difference in response.
 For translational objectives, tissue is obtained at baseline, 3 months, and 6 months.
 Molecular factors, including baseline and change in gene/protein expression in
relevant pathways such as PI3K/AKT, estrogen-regulation, and Wnt signaling, will be
associated with response and resistance to therapy.

Figure 1. The levonorgestrel intrauterine
device (LIUD)

AIM
 This trial will study the levonorgestrel
intrauterine device (LIUD) alone or in
combination with an mTORC1 inhibitor
(everolimus) to overcome progesterone
resistance in AH or stage Ia grade 1 EEC.
 In addition, we will assess clinical,
pathologic, and molecular factors
associated with progesterone resistance.

OBJECTIVES

METHODS

Table 1: Current patient enrollment on LEVER trial

Primary:

 Estimate the efficacy of the LIUD alone to
treat complex atypical hyperplasia or stage Ia
grade 1 endometrioid endometrial carcinoma
with response rate.
 Estimate the efficacy of the LIUD in
combination with everolimus to treat LIUDrefractory complex atypical hyperplasia or
stage Ia grade 1 endometrioid endometrial
carcinoma with response rate.

Secondary:

 Document the toxicity profile of the LIUD
alone or in combination with everolimus
using the NIH- NCI Common Terminology
Criteria for Adverse Events v4.0.
 Estimate overall survival (OS) and event-free
survival (EFS) of patients with complex
atypical hyperplasia or stage Ia grade 1
endometrioid endometrial cancer treated with
the LIUD alone or in combination with
everolimus.
 Estimate the response duration associated
with the LIUD alone or in combination with
everolimus in patients with complex atypical
hyperplasia or stage Ia grade 1 endometrioid
endometrial cancer.

Exploratory:

 Determine if response to therapy can be
predicted based on the molecular profile of
the tumor, including estrogen-induced genes
and relevant pathway members, or by
change in gene expression after therapy

RESULTS
 There have been 57 patients have been
treated with the LIUD during the first stage
of this ongoing study.
 18 patients continued into stage 2 of the
study with 9 being treated with LIUD alone
and 9 with the combination of LIUD and
everolimus.
 To date, tissue has been collected from 16
patients at all three time points.

CONCLUSION
 Tissue collection is feasible in a multicenter
study.
 Analysis of the data collected on study is
ongoing.

